News – PULMONARY HYPERTENSION

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025

A review recently published in the European Respiratory Journal Open Research provides the latest evidence on drug- and toxin-associated pulmonary arterial hypertension, offering clinicians updated guidance on recognition, diagnosis, and management of this pulmonary arterial hypertension subtype (see below for the most recent pulmonary arterial hypertension classification, at 1.3) The first World Health Organization (WHO) […]

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025 Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024

“EXPOSURE” (EUPAS19085) is an observational study describing the characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension initiating a new specific therapy in Europe/Canada. In total, 1.944 patients with follow-up information were included. Most study patients were female with WHO functional class II/III symptoms and idiopathic or connective tissue disorder-associated pulmonary arterial hypertension.

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024 Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate!

📣 Yesterday, August 14 2023, the The Lancet published a ground-breaking three-paper series on pulmonary hypertension. 1️⃣ In the first paper, Prof. Marc Humbert and colleagues provide an overview of the pathophysiology of pulmonary arterial hypertension, current therapeutic approaches, and emerging treatment options, with a forward-looking discussion of innovative solutions for future clinical trials. We

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate! Read Post »